Conditions: Non-Hodgkins Lymphoma
Keywords: velcade temsirolimus non-hodgkins lymphoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 40
Healthy volunteers: no

Brief summary:
The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for multiple myeloma and mantle cell lymphoma, and temsirolimus for renal cell carcinoma) but are not currently approved in combination for B-cell non-Hodgkin lymphoma. The investigators are trying to find out if giving these 2 drugs together will improve the period of time that the patient's cancer is stopped or slowed from growing and causing symptoms.

Detailed description:

Arms:
arm 1: Velcade 1.6 mg/m2 weekly (days 1, 8, 15, and 22) Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)

Treat for up to 6 cycles, cycles are 35 days long.

Interventions: intervention 1: Velcade intervention 2: Temsirolimus
Intervention descriptions: intervention 1: Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22) intervention 2: Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)

Protocol document: